Abstract 5-Aminosalicylic acid (5ASA), 4ASA, their Nacetylated metabolites N-acetyl-5ASA and Nacetyl-4ASA, olsalazine, and colchicine impair interferon-y (IFN y) induced HLA-DR expression on a colonic cell line, HT-29. The mechanism of this effect is now reported. HT-29 cells were cultured with 50 U/ml IFN y with or without drug, and northern blot analysis was performed using a probe for the 1P chain of the DR molecule. IFN y led to a noticeable increase in HLA-DR mRNA which was attenuated by the drugs. Analysis of the specific binding of increasing concentrations of 1251 IFN y by non-linear regression showed a Kd of
Incubation with therapeutic concentrations of drugs led to the following reductions in binding: 10 mM 5ASA, 20% (p<0001); 10 mM N-acetyl-SASA, 24% (p<0.01); 10 mM 4ASA, 21% (p<0.005); 10 mM N-acetyl-4ASA, 29% (p<0.001); and 1 mM olsalazine, 29% (p<0.001). Colchicine (10-7 M) and 10-5 M prednisolone had no effect. Incubation with higher concentrations of the drugs revealed a dose-response effect on binding with complete inhibition by 100 mM 4ASA and 10 mM olsalazine, and lesser degrees of inhibition by 100 mM SASA, N-acetyl-5ASA, and N-acetyl-4ASA. At 4 -aminosalicylic acid (4ASA), prednisolone, and colchicine were purchased from Sigma (Poole, UK). N-acetyl-5ASA, N-acetyl-4ASA, and olsalazine were gifts of Pharmacia AB (Uppsala, Sweden).
Solutions (10 mM) of SASA, 4ASA, and their metabolites were used in most experiments, as the effects of IFN y induced HLA-DR expression were seen at this concentration. '3 Solutions (1 mM) of olsalazine and colchicine (10-7 M) were used for the same reason. The concentrations of SASA and N-acetyl-5ASA are similar to those found in the rectal lumen in patients taking therapeutic doses of SASA-containing compounds.'4 Prednisolone was studied at 10-5 M, which is within the plasma concentration range found in patients taking therapeutic doses of this drug. '5 Solutions of 5ASA, N-acetyl-5ASA, and N-acetyl-4ASA were made by dissolving the drugs in 0.2 M NaOH, diluting 1 in 10 in L-15, and then adjusting to pH 7.4 with 1 M HCI.
Olsalazine and 4ASA were supplied as sodium salts and were dissolved directly in L-15, as was colchicine. Prednisolone was dissolved in dimethylsulphoxide and then diluted 1 in 1000 in L-15 . All solutions were filtered before use.
Methods

NORTHERN BLOT ANALYSIS
Northern blot analysis of HLA-DR and P actin mRNA was performed in the standard manner16 using diethyl pyrocarbonate treated solutions. Briefly, These solutions were mixed with PBS/10% FCS to provide a range of drug concentrations and binding studies were performed as outlined above.
Results
NORTHERN BLOT
As shown in Figure 1, IFN (Fig 2) . All subsequent experiments were performed with 120-240 minute incubations.
Cell viability Trypan blue exclusion was 90-100% after two hours incubation at 4°C in 10 or 100 mM SASA, 4ASA, N-acetyl-5ASA, and N-acetyl-4ASA and IFN a had no effect (Fig 4) . The data presented here suggest that these compounds may act by impairing the binding of IFN y to its receptor on the colonic epithelial cell. It is possible that they may also affect IFN y binding to other cells involved in the colonic mucosal immune response. Although olsalazine was the most potent inhibitor, in vivo measurements have shown that it is almost completely metabolised in the colonic lumen. 14 In contrast, the reduction of IFN y induced epithelial HLA-DR expression by colchicine is not caused by interference with receptor binding. It is more likely to be an intracellular effect of tubulin binding.
As IFN y has such a wide range of effects, an impaired ligand-receptor interaction would modulate the mucosal immune response by a number of mechanisms. Maintenance of low epithelial permeability, inhibition of antigen presentation by epithelial or subepithelial antigen presenting cells, and inhibition of activation or proliferation of immune effector cells could all contribute to the prevention or control of colonic mucosal inflammation.
